Mike Gladstone, global president and general manager of Pfizer Inflammation and Immunology unit, said that the acquisition of Arena is in line with the company’s capabilities and expertise in immunology and inflammatory-related conditions. Over the years, Pfizer has successfully created an innovation engine that develops potential medicines for patients worldwide with chronic and debilitating immuno-inflammatory conditions. The company understands that there is an urgent need to look into other treatment options with high potential, which is where Arena’s cannabinoid-drug pipeline comes in.
Yesterday, Colombian President Gustavo Petro appeared before the UN Commission on Narcotic Drugs, where he…
Before New Constellations started turning heads with dreamy synth-pop and soft-focus heat, Harlee Case was…
In High Times’ new documentary on Rove, one of cannabis culture’s most enduring rituals gets…
The best weed ads don’t feel like ads anymore. They feel like content built to…
“Do you know why I stopped you this evening?” “No sir, I was going the…
Virginia lawmakers have sent a marijuana resentencing bill to Gov. Abigail Spanberger, opening a path…